 |
18 Diseases |  |
3 Trials |
|
3 Trials |  |
15 News |  |
- ||||||||| lithium carbonate ER / Generic mfg.
Trial termination, HEOR: Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies (clinicaltrials.gov) - Feb 15, 2024
P=N/A, N=1037352, Terminated, Sponsor: University of New Mexico
Completed --> Terminated; Per PI, this study is not a clinical trial and was inadvertently entered in the system
- | lithium carbonate ER / Generic mfg.
Journal: Drugs for depressionr. (Pubmed Central) - Dec 26, 2023
Completed --> Terminated; Per PI, this study is not a clinical trial and was inadvertently entered in the system No abstract available
- | Chantix (varenicline) / Pfizer, Aplenzin (bupropion hydrobromide ER) / Bausch Health
Trial completion date, Trial primary completion date: TTOP: Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (clinicaltrials.gov) - Jan 5, 2023
P2, N=96, Recruiting, Sponsor: Joseph Valentino, MD
No abstract available Trial completion date: Mar 2023 --> Jan 2024 | Trial primary completion date: Sep 2022 --> Jan 2024
- ||| lithium carbonate ER / Generic mfg.
Trial completion, HEOR: Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies (clinicaltrials.gov) - Oct 7, 2021
P=N/A, N=1037352, Completed, Sponsor: University of New Mexico
Trial completion date: Mar 2023 --> Jan 2024 | Trial primary completion date: Sep 2022 --> Jan 2024 Enrolling by invitation --> Completed
- || Aplenzin (bupropion hydrobromide ER) / Bausch Health
Trial completion date, Trial primary completion date: Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder (clinicaltrials.gov) - Jun 1, 2021
P4, N=200, Not yet recruiting, Sponsor: Bausch Health Americas, Inc.
Enrolling by invitation --> Completed Trial completion date: Apr 2024 --> Nov 2024 | Trial primary completion date: Apr 2024 --> Nov 2024
- | Chantix (varenicline) / Pfizer, Aplenzin (bupropion hydrobromide ER) / Bausch Health
Enrollment open: TTOP: Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (clinicaltrials.gov) - Jan 31, 2021
P2, N=96, Recruiting, Sponsor: Joseph Valentino, MD
Trial completion date: Apr 2024 --> Nov 2024 | Trial primary completion date: Apr 2024 --> Nov 2024 Not yet recruiting --> Recruiting
- | Chantix (varenicline) / Pfizer, Aplenzin (bupropion hydrobromide ER) / Bausch Health
New P2 trial: TTOP: Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (clinicaltrials.gov) - Nov 17, 2020
P2, N=96, Not yet recruiting, Sponsor: Joseph Valentino, MD
- || Aplenzin (bupropion hydrobromide ER) / Bausch Health
Trial completion date, Trial primary completion date: Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder (clinicaltrials.gov) - Sep 3, 2020
P4, N=200, Not yet recruiting, Sponsor: Bausch Health Americas, Inc.
Not yet recruiting --> Recruiting Trial completion date: Mar 2021 --> Apr 2024 | Trial primary completion date: Nov 2020 --> Apr 2024
- | Journal: Drugs for Depression. (Pubmed Central) - May 13, 2020
Trial completion date: Mar 2021 --> Apr 2024 | Trial primary completion date: Nov 2020 --> Apr 2024 No abstract available
- || Aplenzin (bupropion hydrobromide ER) / Bausch Health
Trial completion date, Trial primary completion date: Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder (clinicaltrials.gov) - Jan 16, 2019
P4, N=200, Not yet recruiting, Sponsor: Valeant Pharmaceuticals International, Inc.
No abstract available Trial completion date: Dec 2017 --> Mar 2021 | Trial primary completion date: Dec 2017 --> Nov 2020
- | lithium carbonate ER / Generic mfg.
Enrollment open, Enrollment change, HEOR: Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies (clinicaltrials.gov) - Oct 13, 2017
P=N/A, N=1300000, Enrolling by invitation, Sponsor: University of New Mexico
Trial completion date: Dec 2017 --> Mar 2021 | Trial primary completion date: Dec 2017 --> Nov 2020 Not yet recruiting --> Enrolling by invitation | N=1000000 --> 1300000
- lithium carbonate ER / Generic mfg.
New trial, HEOR: Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies (clinicaltrials.gov) - Sep 8, 2016
P=N/A, N=1000000, Not yet recruiting, Sponsor: University of New Mexico
- ||| Aplenzin (bupropion hydrobromide ER) / Bausch Health
Trial initiation date: Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder (clinicaltrials.gov) - Jan 22, 2015
P4, N=200, Not yet recruiting, Sponsor: Valeant Pharmaceuticals International, Inc.
Not yet recruiting --> Enrolling by invitation | N=1000000 --> 1300000 Initiation date: Dec 2014 --> Jul 2015
- Aplenzin (bupropion hydrobromide ER) / Bausch Health
Trial completion: Action-HD: Apathy Cure Through Bupropion in Huntington's Disease (clinicaltrials.gov) - Sep 9, 2014
P2, N=40, Completed, Sponsor: Charite University, Berlin, Germany
Initiation date: Dec 2014 --> Jul 2015 Active, not recruiting --> Completed
- ||||| Aplenzin (bupropion hydrobromide ER) / Bausch Health
New P4 trial: Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder (clinicaltrials.gov) - Apr 30, 2014
P4, N=200, Not yet recruiting, Sponsor: Valeant Pharmaceuticals International, Inc.
- Aplenzin (bupropion hydrobromide ER) / Bausch Health
Enrollment closed: Action-HD: Apathy Cure Through Bupropion in Huntington's Disease (clinicaltrials.gov) - Mar 6, 2014
P2, N=40, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Aplenzin (bupropion hydrobromide ER) / Bausch Health
New P2 trial: Action-HD: Apathy Cure Through Bupropion in Huntington's Disease (clinicaltrials.gov) - Jul 31, 2013
P2, N=40, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
- Aplenzin (bupropion hydrobromide ER) / Bausch Health
Biomarker, Enrollment change: Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial. (clinicaltrials.gov) - Aug 20, 2012
P4, N=36, Completed, Sponsor: Stanford University
Recruiting --> Active, not recruiting N=120 --> 36
- Aplenzin (bupropion hydrobromide ER) / Bausch Health
Biomarker, Trial completion: Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial. (clinicaltrials.gov) - Aug 20, 2012
P4, N=36, Completed, Sponsor: Stanford University
N=120 --> 36 Enrolling by invitation --> Completed